A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
A phase 2 trial of Ciltacabtagene autoleucel, Lenalidomide, Daratumumab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma is a phase 2 interventional study registered as NCT04133636 by Janssen Research & Development, LLC, with 208 participants enrolled, started 2019-11-07 and due to reach its primary completion in 2027-02-26. Interventions recorded: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
Shares Ciltacabtagene autoleucel, Bortezomib, Daratumumab, Lenalidomide.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialA Study of Daratumumab
Shares Daratumumab, Dexamethasone, Lenalidomide, Johnson & Johnson.
- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Daratumumab, Dexamethasone, Lenalidomide, Johnson & Johnson.
- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Bortezomib, Daratumumab, Dexamethasone, Lenalidomide.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.